Jazz Pharmaceuticals (JAZZ) Non-Current Debt (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Non-Current Debt of $4.3 billion for Q1 2026, down 19.44% year-over-year from $5.4 billion in Q1 2025, and down 19.3% quarter-over-quarter from $5.4 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Non-Current Debt (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Non-Current Debt history runs 16 years deep, the most recent figure standing at $4.3 billion for Q1 2026.
- In Q1 2026, Non-Current Debt fell 19.44% year-over-year to $4.3 billion; the TTM figure through Mar 2026 stood at $4.3 billion (down 19.44% YoY), while the FY2025 annual figure was $5.4 billion, down 11.84% from the prior year.
- Non-Current Debt for Q1 2026 stood at $4.3 billion, down from $5.4 billion in the prior quarter.
- The five-year high for Non-Current Debt was $6.1 billion in Q3 2024, with the low at $4.3 billion in Q1 2026.
- The 5-year median for Non-Current Debt is $5.7 billion (2023), against an average of $5.5 billion.
- The sharpest annual moves came in 2022 and 2026: Non-Current Debt jumped 223.41% in 2022, then fell 19.44% in 2026.
- Jazz Pharmaceuticals' Non-Current Debt stood at $5.7 billion in 2022, then decreased by 10.28% to $5.1 billion in 2023, then gained by 18.98% to $6.1 billion in 2024, then dropped by 11.84% to $5.4 billion in 2025, then fell by 19.3% to $4.3 billion in 2026.
- Business Quant data shows JAZZ's Non-Current Debt at $4.3 billion in Q1 2026, $5.4 billion in Q4 2025, and $5.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 4.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.35 Bn |
| Mar 31, 2026 | 4.32 Bn |
| Dec 31, 2025 | 5.36 Bn |
| Sep 30, 2025 | 5.36 Bn |
| Jun 30, 2025 | 5.36 Bn |
| Mar 31, 2025 | 5.37 Bn |
| Dec 31, 2024 | 6.08 Bn |
| Sep 30, 2024 | 6.08 Bn |
| Jun 30, 2024 | 5.71 Bn |
| Mar 31, 2024 | 5.11 Bn |
| Dec 31, 2023 | 5.11 Bn |
| Sep 30, 2023 | 5.11 Bn |
| Jun 30, 2023 | 5.69 Bn |
| Mar 31, 2023 | 5.72 Bn |
| Dec 31, 2022 | 5.69 Bn |
| Sep 30, 2022 | 5.73 Bn |
| Jun 30, 2022 | 6.02 Bn |
| Mar 31, 2022 | 5.99 Bn |
| Dec 31, 2021 | 6.05 Bn |
| Sep 30, 2021 | 6.28 Bn |